pharmaceutical investing Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
pharmaceutical investing Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
LaFleur Minerals Closes $1.66 Million Flow-Through Offering to Advance Drilling and PEA-Related Work at its Swanson Gold Deposit
